RUNX1 expression changes are also found in solid tumours, like glioblastoma, ovarian, colon, breast, and hepatocellular carcinoma, where in tumour cells and available patient samples, it predominantly acts as a tumour suppressive. Here, RUNX1 is linked to neoplasm.